Andrew Schiermeier, PhD

Dr. Andrew Schiermeier has spent over two decades as an executive in the biotech and pharmaceutical sectors, with experience from managing operations for startups to directing the strategic expansion of global brands.

Prior to AvenCell, Andrew spent five years serving in a series of successive leadership roles within Intellia Therapeutics, Inc. (most recently as Chief Operating Officer).  Intellia Therapeutics is a world leader in the biotech industry working to harness the genome editing technology CRISPR/Cas9 for human therapeutic use and is the first company to ever demonstrate clinical efficacy in a systemically administered CRISPR-based therapeutic.

Prior to Intellia, Andrew served as Senior Vice President and Global Head of Merck KGaA’s Oncology Business, which spans over 60 countries. While at Merck, he was responsible for rebuilding the company’s oncology pipeline, continuing the growth and expanded indications of Erbitux® (an antibody inhibiting EGFR) and overseeing the development and launch of the world’s first commercialized blood-based biopsy. After successfully partnering the company’s anti-PDL1 antibody Avelumab with Pfizer in a landmark deal in 2014, he also held the position of General Manager of the Merck-Pfizer Immune-Oncology Alliance.

Prior to Merck, Andrew served as the chief operating officer of Aura Biosciences, Inc, a public Cambridge-based biotech harnessing virus like particles (VLPs) for therapeutic applications.  Prior to Aura, he was the chairman and CEO of Medicine in Need Corporation (MEND), an international not-for-profit supported by the Bill & Melinda Gates Foundation aimed at liberating burdened populations from disease of poverty through advanced drug and vaccine delivery. Andrew also served as the CEO of Lantibio, Inc., a private development-stage biotech company with three late-stage compounds in respiratory and ophthalmology therapeutic areas.

Andrew holds a PhD in Applied Mathematics from Harvard University, an MS in Biomechanical Engineering from Stanford University, a B.S. in Mechanical Engineering from Washington University in St. Louis, and an International MBA from College des Ingenieurs in Paris, France.

President & CEO, AvenCell Therapeutics


Join our email list to receive exclusive offers

Opt In